Case no | Year | Sex | Age (years) | Primary diagnosis | Current diagnosis | Karyotype | Treatment | Outcome | References |
---|---|---|---|---|---|---|---|---|---|
1 | 1999 | M | 55 | NHL stage III, gastric cancer | t-AML | 46,XY,t(1;11)(q23;p15) | Topo II inhibitor; MACOP-B | Dead | [5] |
2 | 2007 | M | 74 | Liposarcoma | t-MDS/t-AML | 46,XY,t(1;11)(q23;p15)[17]/46,XY[3] | Doxorubicin, ifosfamide, radiation | Dead | [6] |
3 | 2004 | M | 42 | CML-AP | CML-AP | 46,XY,t(1;11)(q21;p15),t(9; 22)(q34;q11)[30] | Hydrea, Myleran | Dead | [7] |
4 | 2004 | F | 44 | Breast carcinoma | t-AML | 46,XX,t(1;11)(q25;p15)[17]/46,XX[3] | Adriamycin, Cytoxan, 5-FU, BMT | Dead | [7] |
5 | 2006 | M | 51 | CML-CP | AML (CML BP) | 46,XY,t(1;11)(q23;p15),t(9; 22)(q34;q11) | Hydrea; arabinosylcytosine, aclamycin, daunorubicin | – | [8] |
6 | 2020 | M | 49 | De novo AML | De novo AML | 46,XY,t(1;11)(q23;p15)[20] | Idarubicin, cytarabine, BMT | Alive | Current report |